Fisetin: A dietary antioxidant for health promotion

Antioxidants and Redox Signaling

Volumn 19, Issue 2, 2013, Pages 151-162

  Khan, Naghma ^a   Syed, Deeba N ^a   Ahmad, Nihal ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; BIM PROTEIN; CASPASE 3; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DEATH RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FISETIN; FLAVONOID; GELATINASE B; GLUTAMIC ACID; GLUTATHIONE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN E2; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; WNT PROTEIN;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; APPLE; AREA UNDER THE CURVE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CHROMOSOME BREAKAGE; CHROMOSOME LOSS; COLON CANCER; CUCUMBER; CYTOTOXICITY; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; DRUG TRANSFORMATION; FRUIT; GRAPE; HEALTH PROMOTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; LUNG CANCER; MELANOMA; MELANOMA CELL; METASTASIS INHIBITION; NANOEMULSION; NEUROPROTECTION; NONHUMAN; ONION; OXIDATIVE STRESS; PANCREAS CANCER; PERSIMMON; PRIORITY JOURNAL; REVIEW; STRAWBERRY; TUMOR CELL; TUMOR INVASION; VEGETABLE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; DIET; FLAVONOIDS; HEALTH PROMOTION; HUMANS; NEOPLASMS;

ALLIUM CEPA; ANIMALIA; CUCUMIS SATIVUS; DIOSPYROS; FRAGARIA X ANANASSA; MALUS X DOMESTICA; VITACEAE;

EID: 84879140852     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4901     Document Type: Review

References (74)

1. Adhami VM, Khan N, and Mukhtar H. Cancer chemoprevention by pomegranate: laboratory and clinical evidence. Nutr Cancer 61: 811-815, 2009.
2. Adhami VM, Syed D, Khan N, and Mukhtar H. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol 84: 1277-1281, 2012.
3. Angelini A, Di Ilio C, Castellani ML, Conti P, and Cuccurullo F. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin-resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. J Biol Regul Homeostat Agents 24: 197-205, 2010.
4. Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R, and Kinae N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 130: 2243-2250, 2000.
5. Arbiser JL and Fisher DE. Fisetin: a natural fist against melanoma? J Invest Dermatol 131: 1187-1189, 2011.
6. Aruoma OI. Methodological considerations for characterizing potential antioxidant actions of bioactive components in plant foods. Mutat Res 523: 9-20, 2003.
7. Beecher GR. Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 133: 3248S-3254S, 2003.
8. Burdo J, Schubert D, and Maher P. Glutathione production is regulated via distinct pathways in stressed and non-stressed cortical neurons. Brain Res 1189: 12-22, 2008.
9. Chen WS, Lee YJ, Yu YC, Hsaio CH, Yen JH, Yu SH, Tsai YJ, and Chiu SJ. Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin. Int J Radiat Oncol Biol Phys 77: 1527-1535, 2010.
10. Chen YC, Shen SC, Lee WR, Lin HY, Ko CH, Shih CM, and Yang LL. Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol 76: 351-359, 2002.
11. Chien CS, Shen KH, Huang JS, Ko SC, and Shih YW. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem 333: 169-180, 2010.
12. Dela Cruz CS, Tanoue LT, and Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32: 605-644, 2011.
13. Duarte J, Perez-Vizcaino F, Zarzuelo A, Jimenez J, and Tamargo J. Vasodilator effects of quercetin in isolated rat vascular smooth muscle. Eur J Pharmacol 239: 1-7, 1993.
14. Fahey JW, Talalay P, and Kensler TW. Notes from the field: green chemoprevention as frugal medicine. Cancer Prev Res (Phila) 5: 179-188, 2012.
15. Firuzi O, Lacanna A, Petrucci R, Marrosu G, and Saso L. Evaluation of the antioxidant activity of flavonoids by ferric reducing antioxidant power assay and cyclic voltammetry. Biochim Biophys Acta 1721: 174-184, 2005.
16. Funakoshi-Tago M, Nakamura K, Tago K, Mashino T, and Kasahara T. Anti-inflammatory activity of structurally related flavonoids, apigenin, luteolin and fisetin. Int Immunopharmacol 11: 1150-1159, 2011.
17. Gelderblom M, Leypoldt F, Lewerenz J, Birkenmayer G, Orozco D, Ludewig P, Thundyil J, Arumugam TV, Gerloff C, Tolosa E, Maher P, and Magnus T. The flavonoid fisetin attenuates postischemic immune cell infiltration, activation and infarct size after transient cerebral middle artery occlusion in mice. J Cereb Blood Flow Metab 32: 835-843, 2012.
18. Gordon MH, Roedig-Penman A. Antioxidant activity of quercetin and myricetin in liposomes. Chem Phys Lipids 97: 79-85, 1998.
19. Haddad AQ and Fleshner N, Nelson C, Saour B, Musquera M, Venkateswaran V, Klotz L. Antiproliferative mechanisms of the flavonoids 2,2-dihydroxychalcone and fisetin in human prostate cancer cells. Nutr Cancer 62: 668-681, 2010.
20. Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, and Klotz LH. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 9: 68-76, 2006.
21. Hiipakka RA, ZhangHZ, DaiW,Dai Q, and Liao S. Structureactivity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol 63: 1165-1176, 2002.
22. Hou DX, Fukuda M, Johnson JA, Miyamori K, Ushikai M, and Fujii M. Fisetin induces transcription of NADPH: quinone oxidoreductase gene through an antioxidant responsive element-involved activation. Int J Oncol 18: 1175-1179, 2001.
23. Ishige K, Schubert D, and Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 30: 433-446, 2001.
24. Jang HS, Kook SH, Son YO, Kim JG, Jeon YM, Jang YS, Choi KC, Kim J, Han SK, Lee KY, Park BK, Cho NP, and Lee JC. Flavonoids purified from Rhus verniciflua stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochim Biophys Acta 1726: 309-316, 2005.
25. Jankun J, Selman SH, Aniola J, and Skrzypczak-Jankun E. Nutraceutical inhibitors of urokinase: potential applications in prostate cancer prevention and treatment. Oncol Rep 16: 341-346, 2006.
26. Khan N, Adhami VM, and Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer 17: R39-R52, 2010.
27. Khan N, Afaq F, Khusro FH, Mustafa Adhami V, Suh Y, and Mukhtar H. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Int J Cancer 130: 1695-1705, 2012.
28. Khan N, Afaq F, and Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10: 475-510, 2008.
29. Khan N, Afaq F, Syed DN, and Mukhtar H. Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells. Carcinogenesis 29: 1049-1056, 2008.
30. Khan N, Asim M, Afaq F, Abu Zaid M, and Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res 68: 8555-8563, 2008.
31. Kim J, Kundu M, Viollet B, and Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13: 132-141, 2011.
32. Kim SC, Kang SH, Jeong SJ, Kim SH, and Ko HS. Inhibition of c-Jun N-terminal kinase and nuclear factor kappa B pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysccharide-treated RAW264.7 cells. Immunopharmacol Immunotoxicol 34: 645-650, 2012.
33. Kimira M, Arai Y, Shimoi K, and Watanabe S. Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol 8: 168-175, 1998.
34. Kuhnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 24: 117-191, 1976.
35. Kuntz S, Wenzel U, and Daniel H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr 38: 133-142, 1999.
36. Lee SE, Jeong SI, Yang H, Park CS, Jin YH, and Park YS. Fisetin induces Nrf2-mediated HO-1 expression through PKC-delta and p38 in human umbilical vein endothelial cells. J Cell Biochem 112: 2352-2360, 2011.
37. Lian TW, Wang L, Lo YH, Huang IJ, and Wu MJ. Fisetin, morin and myricetin attenuate CD36 expression and oxLDL uptake in U937-derived macrophages. Biochim Biophys Acta 1781: 601-609, 2008.
38. Liao YC, Shih YW, Chao CH, Lee XY, and Chiang TA. Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549. J Agric Food Chem 57: 8933-8941, 2009.
39. Lim do Y and Park JH. Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Am J Physiol Gastrointest Liver Physiol 296: G1060-G1068, 2009.
40. Lu W, Zhu J, Zou S, Li X, and Huang J. The efficient expression of human fibroblast collagenase in Escherichia coli and the discovery of flavonoid inhibitors. J Enzyme Inhib Med Chem 2012 [Epub ahead of print]; DOI: 10 3109/14756366.2012.681650.
41. Lu X, Jung J, Cho HJ, Lim DY, Lee HS, Chun HS, Kwon DY, and Park JH. Fisetin inhibits the activities of cyclindependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells. J Nutr 135: 2884-2890, 2005.
42. Maher P. Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. Genes Nutr 4: 297-307, 2009.
43. Maher P, Akaishi T, and Abe K. Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc Natl Acad Sci U S A 103: 16568-16573, 2006.
44. Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, and Marsh JL. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet 20: 261-270, 2011.
45. Maher P, Salgado KF, Zivin JA, and Lapchak PA. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res 1173: 117-125, 2007.
46. Markovic ZS, Mentus SV, and Dimitric Markovic JM. Electrochemical and density functional theory study on the reactivity of fisetin and its radicals: implications on in vitro antioxidant activity. J Phys Chem A 113: 14170-14179, 2009.
47. Mohapatra M and Mishra AK. Photophysical behavior of fisetin in dimyristoylphosphatidylcholine liposome membrane. J Phys Chem B 115: 9962-9970, 2011.
48. Murtaza I, Adhami VM, Hafeez BB, Saleem M, and Mukhtar H. Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappa B. Int J Cancer 125: 2465-2473, 2009.
49. Myara I, Pico I, Vedie B, and Moatti N. A method to screen for the antioxidant effect of compounds on low-density lipoprotein (LDL): illustration with flavonoids. J Pharmacol Toxicol Methods 30: 69-73, 1993.
50. Nagai K, Takahashi Y, Mikami I, Fukusima T, Oike H, and Kobori M. The hydroxyflavone, fisetin, suppresses mast cell activation induced by interaction with activated T cell membranes. Br J Pharmacol 158: 907-919, 2009.
51. Nguyen H, Zhang S, and Morris ME. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharmaceut Sci 92: 250-257, 2003.
52. Olaharski AJ, Mondrala ST, and Eastmond DA. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin. Mutat Res 582: 79-86, 2005.
53. Ragelle H, Crauste-Manciet S, Seguin J, Brossard D, Scherman D, Arnaud P, and Chabot GG. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int J Pharm 427: 452-459, 2012.
54. Ravichandran N, Suresh G, Ramesh B, and Siva GV. Fisetin, a novel flavonol attenuates benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Food Chem Toxicol 49: 1141-1147, 2011.
55. Rice-Evans CA, Miller NJ, and Paganga G. Structureantioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 20: 933-956, 1996.
56. Sagara Y, Vanhnasy J, and Maher P. Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal-regulated kinase activation. J Neurochem 90: 1144-1155, 2004.
57. Salmela AL, Pouwels J, Varis A, Kukkonen AM, Toivonen P, Halonen PK, Perala M, Kallioniemi O, Gorbsky GJ, and Kallio MJ. Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. Carcinogenesis 30: 1032-1040, 2009.
58. Scalbert A and Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 130: 2073S-2085S, 2000.
59. Sengupta B, Banerjee A, and Sengupta PK. Investigations on the binding and antioxidant properties of the plant flavonoid fisetin in model biomembranes. FEBS Lett 570: 77-81, 2004.
60. Shia CS, Tsai SY, Kuo SC, Hou YC, and Chao PD. Metabolism and pharmacokinetics of 3,3,4,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J Agric Food Chem 57: 83-89, 2009.
61. Suh Y, Afaq F, Johnson JJ, and Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappa B-signaling pathways. Carcinogenesis 30: 300-307, 2009.
62. Suh Y, Afaq F, Khan N, Johnson JJ, Khusro FH, and Mukhtar H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis 31: 1424-1433, 2010.
63. Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med 8: 583-599, 1990.
64. Sung B, Pandey MK, and Aggarwal BB. Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factorkappa B-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol Pharmacol 71: 1703-1714, 2007.
65. Syed DN, Afaq F, Maddodi N, Johnson JJ, Sarfaraz S, Ahmad A, Setaluri V, and Mukhtar H. Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/beta-catenin signaling and decreased Mitf levels. J Invest Dermatol 131: 1291-1299, 2011.
66. Syed DN, Suh Y, Afaq F, and Mukhtar H. Dietary agents for chemoprevention of prostate cancer. Cancer Lett 265: 167-176, 2008.
67. Szliszka E, Helewski KJ, Mizgala E, and Krol W. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells. Int J Oncol 39: 771-779, 2011.
68. Touil YS, Auzeil N, Boulinguez F, Saighi H, Regazzetti A, Scherman D, and Chabot GG. Fisetin disposition and metabolism in mice: identification of geraldol as an active metabolite. Biochem Pharmacol 82: 1731-1739, 2011.
69. Touil YS, Seguin J, Scherman D, and Chabot GG. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemother Pharmacol 68: 445-455, 2011.
70. Vanden Berghe W. Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol Res 65: 565-576, 2012.
71. Yang PM, Tseng HH, Peng CW, Chen WS, and Chiu SJ. Dietary flavonoid fisetin targets caspase-3-deficient human breast cancer MCF-7 cells by induction of caspase-7-associated apoptosis and inhibition of autophagy. Int J Oncol 40: 469-478, 2012.
72. Yu SH, Yang PM, Peng CW, Yu YC, and Chiu SJ. Securin depletion sensitizes human colon cancer cells to fisetininduced apoptosis. Cancer Lett 300: 96-104, 2011.
73. Zhen L, Zhu J, Zhao X, Huang W, An Y, Li S, Du X, Lin M, Wang Q, Xu Y, and Pan J. The antidepressant-like effect of fisetin involves the serotonergic and noradrenergic system. Behavior Brain Res 228: 359-366, 2012.
74. Zheng LT, Ock J, Kwon BM, and Suk K. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int Immunopharmacol 8: 484-494, 2008.